Previous close | 262.13 |
Open | 260.91 |
Bid | 260.07 x 800 |
Ask | 263.45 x 800 |
Day's range | 262.70 - 264.39 |
52-week range | 161.65 - 275.00 |
Volume | |
Avg. volume | 558,926 |
Market cap | 13.506B |
Beta (5Y monthly) | 1.39 |
PE ratio (TTM) | 28.50 |
EPS (TTM) | 9.23 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 264.07 |
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.